Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Entecavir (ETV) has shown superior ability to suppress hepatitis B virus (HBV) replication,
histology improvement as well as low rate of emergence of resistant mutants. Out of range of
clinical recommendations for treatment of chronic hepatitis B (CHB), chronic HBV carriers
with persistently normal ALT and viral load more than 10^5 copies/mL have progression of
liver disease during long-term follow-up. In addition, certain proportions of these patients
do have significant inflammation and fibrosis in liver histology. This study will be able to
identify who are at risk of liver disease progression and evaluate efficacy of ETV regarding
improvement of liver histology during short-term (1-year) and long-term ETV treatment
(3-year).